Despite significant reduction in mortality in ST-segment elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI), mortality rates in AMI complicated by cardiogenic shock (AMI-CGS) continues to be unacceptably high at about 50%.1 Percutaneous ventricular assist devices (pVADS) such as Impella® heart pumps have emerged as a promising therapeutic option for AMI-CGS, owing to its … Continue reading “Early Initiation of Impella Support Pre-PCI: Key to Consistent and Reproducible Outcome of Improved Survival in AMICS”
Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) database. The clinical publication highlights best practice protocols based on real-world evidence that is showing improved outcomes in cardiogenic shock. This clinical evidence is derived from Abiomed’s observational , commercial IQ database. In patients with AMICS receiving … Continue reading “Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device”
Early vs Late Impella® Device Support is Associated with a Better Survival Benefit in AMICS: A Meta-Analysis
Reference: Flaherty MP et al. JACC Cardiovasc Interv. 2017;10(17):1805-1806. Key Takeaways In patients with acute myocardial infarction complicated by cardiogenic shock (AMICS), early mechanical circulatory support with the Impella® device is associated with a greater survival advantage compared with post-revascularization support. According to a meta-analysis by Flaherty et al, the initiation of early Impella® support … Continue reading “Early vs Late Impella® Device Support is Associated with a Better Survival Benefit in AMICS: A Meta-Analysis”
Impella 2.5® Device Support Prior to Unprotected Left Main PCI is Associated with Improved Survival Among AMICS Patients
Key Takeaways In the setting of acute myocardial infarction (AMI) cardiogenic shock (CS), Impella® device prior to percutaneous coronary intervention (PCI) has been associated with a survival benefit. Researchers assessed outcomes of patients supported with Impella 2.5® prior to and after PCI on an unprotected left main coronary artery (ULMCA) culprit lesion in the setting … Continue reading “Impella 2.5® Device Support Prior to Unprotected Left Main PCI is Associated with Improved Survival Among AMICS Patients”
Case Review: AMI Cardiogenic Shock using Impella CP® Heart Pump Support on a Left Main During Orbital Atherectomy
Dr. David Lasorda of Allegheny General Hospital presents a case of AMI cardiogenic shock using Impella CP® Heart Pump Support on a left main involving Orbital Atherectomy. The patient is an 86 year old who was admitted to a community hospital in respiratory distress, was intubated and sent to a tertiary hospital where severe coronary … Continue reading “Case Review: AMI Cardiogenic Shock using Impella CP® Heart Pump Support on a Left Main During Orbital Atherectomy”
Retrospective Registry Data Suggests that Early Impella® Support is Associated with Increased Survival in Cardiogenic Shock
- This retrospective study evaluated observational data of patients receiving either early or delayed initiation of Impella for the management of acute myocardial infarction complicated by cardiogenic shock (AMICS).
- Receiving mechanical circulatory support (MCS) prior to percutaneous coronary intervention (PCI) compared with post-PCI initiation was associated with a higher survival rate to discharge among AMICS patients.
- Overall survival to discharge for the cohort was 44%.
- Additionally, early initiation of MCS at the first signs of shock and before inotropes, vasopressors, and PCI correlated with a higher rate of survival.